Drug intelligence / Profile preview

AGS-1

Development stage: Unknown
Lead developer: Medika Natura
Modality: Small Molecules

Overview

AGS-1 is a botanical-derived drug candidate developed by the Indonesian biotechnology company Medika Natura. It is being developed as an immunomodulator and for the treatment of upper respiratory tract infections (URTI). The compound is produced using proprietary fractionation technology to isolate specific bioactive components from natural sources. In addition to its development as a monotherapy, AGS-1 is being studied in combination with SKF7 for its potential activity against SARS-CoV-2.

Beyond the preview

Go deeper on AGS-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AGS-1.

Explore the full profile